Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: Standard of care or an experimental approach?

The Lancet Oncology

Volumn 13, Issue 8, 2012, Pages

  Sugarbaker, Paul H ^a   Ryan, David P ^b,c  

^a WASHINGTON CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COLON CANCER; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE SPECIFIC SURVIVAL; EXPERIMENTAL THERAPY; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; HYPERTHERMIC THERAPY; LONG TERM SURVIVAL; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; NOTE; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERITONEAL CAVITY; PERITONEAL DISEASE; PERITONEUM METASTASIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOTHERMIA, INDUCED; PATIENT SELECTION; PERIOPERATIVE CARE; PERITONEAL NEOPLASMS; PERITONEUM; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STANDARD OF CARE; TREATMENT OUTCOME;

EID: 84864359911     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70210-3     Document Type: Note

References (44)

1. Sugarbaker PH. Surgical debulking and hyperthermic chemotherapy for metastatic colon cancer: if you select the right patients, long term survival can be achieved. ASCO Annual Meeting; Chicago, IL; June 3-7, 2011.
2. Ryan DP. Surgical debulking and hyperthermic chemotherapy for metastatic colon cancer: stop selecting patients and start proving efficacy. ASCO Annual Meeting; Chicago, IL; June 3-7, 2011.
3. Sugarbaker PH, Jablonski KA Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995, 221:124-132.
4. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003, 21:3737-3743.
5. Shen P, Hawksworth J, Lovato J, et al. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004, 11:178-186.
6. Franko J, Ibrahim Z, Gusani NJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010, 116:3756-3762.
7. Sugarbaker PH Peritonectomy procedures. Surg Oncol Clin N Am 2003, 12:703-727.
8. Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacologic studies. Cancer Res 1990, 50:5790-5794.
9. Jacquet P, Sugarbaker PH Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 1996, 15:49-58.
10. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010, 28:63-68.
11. da Silva RG, Sugarbaker PH Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg 2006, 203:878-886.
12. Elias D, Goere D, Di Pietrantonio D, et al. Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008, 247:445-450.
13. Mohamed F, Moran BJ Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy. The importance of a learning curve. Cancer J 2009, 15:196-199.
14. Sugarbaker PH, van der Speeten K, Stuart OA, Chang D, Mahteme H Patient- and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas 2012, Cine-Med, Woodbury, CT. P.H. Sugarbaker (Ed.).
15. Chua TC, Yan TD, Saxena A, Morris DL Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 2009, 249:900-907.
16. Libutti SK, Saltz LB, Willett G Cancer of the colon. Cancer: principles and practice of oncology 2010, 1084-1126. JB Lippincott, Philadelphia, PA. 9th edn. V.T. De Vita, T.S. Lawrence, S.A. Rosenberg (Eds.).
17. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTG's phase III trials N9741 and N9841. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 3571.
18. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008, 15:2426-2432.
19. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004, 22:3284-3292.
20. Yan TD, Black D, Savady R, Sugarbaker PH Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006, 24:4011-4019.
21. Verwaal VJ Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer J 2009, 15:212-215.
22. Jayne DG, Fook S, Loi C, Seow-Choen F Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002, 89:1545-1550.
23. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006, 243:212-222.
24. Dy GK, Hobday TJ, Nelson G, et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin Colorectal Cancer 2009, 8:88-93.
25. Dy GK, Krook JE, Green EM, et al. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. J Clin Oncol 2007, 25:3469-3474.
26. Grothey A, Sargent D Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005, 23:9441-9442.
27. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
28. Van Cutsem E, Bajetta E, Valle J, et al. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 2011, 29:2004-2010.
29. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29:2011-2019.
30. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27:3677-3683.
31. van der Burg ME, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995, 332:629-634.
32. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 2004, 351:2489-2497.
33. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010, 363:943-953.
34. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318.
35. Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw 2009, 7:778-831.
36. Dedrick RL, Myers CE, Bungay PM, DeVita VT Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978, 62:1-11.
37. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
38. Hess LM, Benham-Hutchins M, Herzog TJ, et al. A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 2007, 17:561-570.
39. Aarts F, Hendriks T, Boerman OC, Koppe MJ, Oyen WJ, Bleichrodt RP A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. Ann Surg Oncol 2007, 14:3274-3282.
40. Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967, 20:1351-1381.
41. Hildebrandt B, Wust P Interactions between hyperthermia and cytotoxic drugs. Cancer Treat Res 2007, 134:185-193.
42. Gonzalez-Moreno S, Gonzalez-Bayon LA, Ortega-Perez G Hyperthermic intraperitoneal chemotherapy: rationale and technique. World J Gastrointest Oncol 2010, 2:68-75.
43. Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP, de Hingh IH Intraoperative versus early postoperative intraperitoneal chemotherapy after cytoreduction for colorectal peritoneal carcinomatosis: an experimental study. Ann Surg Oncol 2011, published online Aug 12. 10.1245/s10434-011-1984-9.
44. Rettig RA, Jacobson PD, Farquhar CM, Aubry WM False hope: bone marrow transplantation for breast cancer 2007, Oxford University Press, New York, NY.